NEW YORK, NY, Nectar, an innovative and comprehensive allergy care platform, announced today its $16.5 million Series A round.
The round was led by Harmony Partners, with meaningful participation from founding partners Juxtapose and Obvious Ventures, who co-built the company with Founding CEO Kenneth Chahine, Ph.D.
Nectar is building a comprehensive, vertically integrated allergy healthcare platform that leverages data and clinical research to offer a personalized, patient-centric approach to allergy care. Led by founder and CEO Kenneth Chahine, Nectar is the direct-to-consumer brand developed by Nectar Life Sciences.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about